The objective of this review is to evaluate the safety and efficacy of pharmacotherapy for long-term maintenance of weight loss in overweight and obese patients. Literature was obtained through a MEDLINE (1966 to July 2006) search and a bibliographic review of published articles. Key terms used included overweight, obesity, sibutramine, orlistat, and rimonabant. The search was further limited to clinical trials in humans and in the English language. Obesity is a chronic condition requiring long-term therapy. Two agents, sibutramine and orlistat, are currently approved by the Food and Drug Administration for the long-term treatment of obesity. Rimonabant, marketed in Europe as Accomplia, has demonstrated efficacy for long term weight loss, however an Food and Drug Administration advisory panel voted against its approval in June 2007 due to safety concerns (psychiatric effects). For clinically meaningful results, these agents must be used in conjunction with lifestyle therapy, including a hypocaloric diet, increased physical activity, and behavioral modification. This article reviews clinical trials evaluating the safety and efficacy of sibutramine, orlistat, and rimonabant in reducing weight and examines other health benefits and risks associated with these agents.
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KMPrevalence of overweight and obesity in the United States, 1999-2004. JAMA.2006;295:1549-1555.
2.
Must A., Spadano J., Coakley EH, Field A., Colditz G., Dietz WHThe disease burden associated with overweight and obesity. JAMA.1999;282:1523-1529.
3.
National Institutes of Health, National Heart, Lung and Blood Institute, North American Association for the Study of Obesity.The Practical Guide: Identification, Evaluation and Treatment of Overweight and Obesity in Adults. NIH Pub. 00-4084, October 2000. Available at: http://www.nhlbi.nih.gov/guidelines/obesity/prctgd_c.pdf . Accessed July 21, 2006.
4.
Wilson Pwf, D'Agostino RB, Sullivan L., Parise H., Kannel WBOverweight and obesity as determinants of cardiovascular risk, the Framingham experience. Arch Intern Med.2002;162:1867-1872.
5.
National Task Force on the Prevention and Treatment of Obesity.Overweight, obesity, and health risk . Arch Intern Med.2000;160:898-904.
6.
Mertens IL, VanGaal LF. Overweight, obesity, and blood pressure: the effects of modest weight reduction. Obes Res.2000;8:270-278.
7.
Goldstein DJBeneficial health effects of modest weight loss. Int J Obes Relat Metab Disord.1992;16:397-415.
8.
Sarlio-Lähteenkorva S., Rissanen A., Kaprio J.A descriptive study of weight loss maintenance: 6 and 15 year follow up of initially overweight adults. Int J Obes.2000;24:116-125.
9.
Padwal R., Li SK, Lau Dcw.Long term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes.2003;27:1437-1446.
10.
Ioannides-Demos LL, Proietto J., McNeil JJPharmacotherapy for obesity. Drugs. 2005;65:1391-1418.
11.
Boyd ST, Fremming BARimonabant— a selective CB1 antagonist. Ann Pharmacother.2005;39:684-690.
Phentermine hydrochloride USP [complete product information] . Little Falls, NJ: Amide Pharmaceuticals, Inc; 1997.
15.
Haddock CK, Poston Wsc, Dill PL, Foreyt JP, Ericsson M.Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes.2002 ;26:262-273.
16.
Food and Drug Administration.FDA announces withdrawal of fenfluramine and dexfenfluramine. September 15, 1997. Available at: http://www.fda.gov/cder/news/phen/fenphenpr81597.htm. Accessed July 21, 2006.
Food and Drug Administration Center for Drug Evaluation and Research.Summary of minutes of the Endocrinologic and Metabolic Drugs Advisory Committee meeting on June 13, 2007. Available at: http://www.fda.gov/ohrms/dockets/ac/07/minutes/2007-4306m1-final.pdf Accessed July 11, 2007.
20.
VanGaal LF, Rissanen A, Scheen A, Ziegler O, Rössner S, for the RIO-Europe Study Group. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIOEurope study. Lancet. 2005;365:1389-1397.
21.
Pi-Sunyer FX , Aronne LJ, Heshmati HM, Devin J., Rosenstock J., for the RIO-North America Study Group.Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients. RIO-North America: a randomized controlled trial. JAMA.2006;295:761-775.
22.
Halford Jcg.Pharmacotherapy for obesity. Appetite. 2006;46:4-10.
23.
Hanotin C., Thomas F., Jones SP, Leutenegger, Drouin P.Efficacy and tolerability of sibutramine in obese patients: a dose ranging study. Int J Obes.1998;22:32-38.
24.
Weintraub M. , Rubio A., Golik A., Byrne L., Scheinbaum MLSibutramine in weight control: a dose-ranging, efficacy study. Clin Pharmacol Ther.1991;50:330-337.
25.
Smith IG, Goulder MARandomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity. J Fam Pract.2001;50:505-512.
26.
Wadden TA, Berkowitz RI, Sarwer DB, Prus-Wisniewski R., Steinberg C.Benefits of lifestyle modifications in the pharmacologic treatment of obesity: a randomized trial. Arch Intern Med.2001;161:218-227.
27.
Porter JA, Raebel MA, Conner DA, et al. The Long-term Outcomes of Sibutramine Effectiveness on Weight (LOSE Weight) study: evaluating the role of drug therapy within a weight management program in a group-model health maintenance organization. Am J Manag Care.2004;10:369-376.
28.
Apfelbaum M. , Vague P., Ziegler O., Hanotin C., Thomas F, Leutenegger.Long-term maintenance of weight loss after a very-low-calorie diet: a randomized blinded trial of the efficacy and tolerability of sibutramine. Am J Med.1999;106:179-184.
29.
Fanghänel G. , Cortinas L., Sanchez-Reyes L., Berber A.A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes.2000;24:144-150.
30.
Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med.2005;353:2111-2120.
31.
Wirth A., Krause J.Long-term weight loss with sibutramine. JAMA.2001;286:1331-1339.
32.
Cuellar Gem , Ruiz AM, Monsalve Mcr, Berber A.Six month treatment of obesity with sibutramine 15mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res.2000;8:71-82.
33.
James WP, Astrup A., Finer N., et al. Effect of sibutramine on weight maintenance after weight loss: a randomized trial. Lancet. 2000;356:2119-2125.
34.
Mathus-Vliegen Emh.Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study. Eur J Clin Nutr.2005;59:s31-s39.
35.
Hauner H., Meier M., Wendland G., Kurscheid T., Lauterbach K.Weight reduction by sibutramine in obese subjects in primary care medicine: The S.A.T study. Exp Clin Endocrinol Diabetes.2004;112:201-207.
36.
Hansen DL, Astrup A., Toubro S., et al. Predictors of weight loss and maintenance during 2 years of treatment by sibutramine in obesity: results from the European multi-centre STORM trial. Int J Obes.2001;25:496-501.
37.
Finer N., Bloom SR, Frost GS, Banks LM, Griffiths J.Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study. Diabetes Obes Metab. 2000;2:105-112.
38.
Gokcel A., Karakose H., Ertorer EM, Tanaci N., Tutuncu NB, Guvener N.Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control. Diabetes Care. 2001 ;24:1957-1960.
39.
Kaukua JK, Pekkarinen TA, Rissanen AMHealth-related quality of life in a randomised placebo-controlled trial of sibutramine in obese patients with type II diabetes. Int J Obes.2004;28:600-605.
40.
McNulty SJ, Ehud U., Williams G.A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin. Diabetes Care. 2003;26:125-131.
41.
Redmon JB, Reck KP, Raatz SK, et al. Twoyear of a combination of weight loss therapies for type 2 diabetes. Diabetes Care. 2005;28:1311-1315.
42.
Serrano-Rios M., Melchionda N., MorenoCarreterot E.Role of sibutramine in the treatment of obese type 2 diabetic patients receiving sylphonylurea therapy . Diabetes Med.2002;19:119-124.
43.
Tankova T., Dakovska G., Lazarova M., Dakovska L., Kirilov G., Koev D.Sibutramine in the treatment of obesity in type 2 diabetic patients and in nondiabetic subjects. Acta Diabetol.2004;41:146-153.
44.
Wang TF, Pei D, Li Jc, et al. Effects of sibutramine in overweight, poorly controlled Chinese female type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. In J Clin Pract. 2005;59:746-750.
45.
Bray GASibutramine and blood pressure: a therapeutic dilemma. J Hum Hypertens. 2002;16:1-3.
46.
Faria AN, Filho Ffr, Kohlmann NE, Ferreira Srg, Zanella MTEffects of siburamine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients. Diabetes Obes Metab . 2005;7:246-253.
47.
Hazenberg BP , Ziekenhuis AS, Amsteiwijk, et al. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients. Cardiology. 2000;94:152-158.
48.
McMahon FG, Fujioka K., Singh BN, et al. Efficacy and safety of sibutramine in obese white and African American patients with hypertension. Arch Intern Med.2000;160:2185-2191.
49.
Sramek JJ, Leibowitz MT, Weinstein SP, et al. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by β-adrenergic blocking agents: a placebo-controlled, double-blind, randomized trial. J Hum Hypertens. 2002;16:13-19.
50.
McMahon FG, Weinstein SP, Rowe E., et al. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors . J Hum Hypertens. 2002;16:5-11.
51.
Dujovne CA, Zavoral JH, Rowe E., Mendel CMEffects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia . Am Heart J.2001;142:489-497.
52.
Berkowitz RI , Fujioka K., Daniels SR, et al. Effects of sibutramine treatment in obese adolescents. Ann Intern Med.2006;145:81-90.
53.
Godoy-Matos A., Carraro L., Viera A., et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab.2005;90:1460-1465.
54.
Berkowitz RI , Wadden TA, Tershakovec AM, Cronquist JLBehavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA.2003;289:1805-1812.
55.
Reisler G., Tauber T., Afriat R., Bortnik O., Goldman M.Sibutramine as an adjuvant therapy in adolescents suffering from morbid obesity . IMAJ. 2006;8:30-32.
56.
Drent ML, Larsson I., William-Olsson T., et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity: a multiple dose study. Int J Obes.1995;19:221-226.
57.
Hauptman JB , Jeunet GS, Hartmann D.Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am J Clin Nutr.1992;55:309S-313S.
58.
VanGaal LF, Broom JI, Enzi G, for The Orlistat Dose-Ranging Study Group. Efficacy and tolerability of orlistat in the treatment of obesity: a 6 month dose-ranging study. Eur J Clin Pharmacol.1998;54:125-132.
59.
Drent ML, van der Veen EALipase inhibition: a novel concept in the treatment of obesity. Int J Obes.1993;17:241-244.
60.
GlaxoSmithKline.FDA joint advisory committee recommends approval of orlistat 60mg capsules for over-the-counter use. Available at: http://www.gsk.com/ControllerServlet?appId-4&pageId=402&newsid+725 . Accessed July 27, 2006.
61.
Anderson JW , Schwartz SM, Hauptman J., et al. Low-dose orlistat effects on body weight of mildly to moderately overweight individuals: a 16 week, double-blind, placebo-controlled trial. Ann Pharmacother.2006;40:1717-1723.
62.
Rössner S., Sjöström L., Noack R., Meinders AE, Noseda G.Weight loss, weight maintenance and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. Obes Res.2000;8:49-61.
63.
O'Meara S., Riemsma R., Shirran L., Mather L., ter Tiet G.A systematic review of the clinical effectiveness of orlistat used for the management of obesity. Obes Rev. 2004;5:51-68.
64.
Sjöström L. , Rissanen A., Andersen T., et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of regain in obese patients. Lancet. 1998;352:167-172.
65.
Hill, JO, Hauptman J., Anderson JW, et al. Orlistat, a lipase inhibitor for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr.1999 ;69:1108-1116.
66.
Cavaliere H. , Floriano I., Medeiros-Neto G.Gastrointestinal side effects of orlistat may be prevented by concomitant prescription of natural fibers (psyllium mucilloid) . Int J Obes.2001;25:1095-1099.
67.
Fox M., Stutz B., Menne D., Fried M., Schwizer W., Thumshirn M.The effects of loperamide on continence problems and anorectal function in obese subjects taking orlistat. Dig Dis Sci.2005;9:1576-1583.
68.
Melia AT, Koss-Twardy SG, Zhi J.The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol.1996;36:647-653.
69.
Zhi J., Melia AT, Koss-Twardy SG, Arora S., Patel IHThe effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of β-carotene in healthy volunteers. J Clin Pharmacol.1996;36:152-159.
70.
Davidson MH, Hauptman J., DiGirolamo M.Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA.1999;281:235-242.
71.
Finer N., James Wpt, Kopelman PB, Lean Mej, Williams G.One-year treatment of obesity: a randomized double blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor. Int J Obes.2000;24:306-313.
72.
Togerson JS , Hauptman J., Boldrin MN, Sjöström L.Xenical in the prevention of diabetes in obese subjects (XENDOS) study. Diabetes Care. 2004 ;27:155-161.
73.
Hauptman J. , Lucas C., Boldrin MN, Collins H., for the Orlistat Primary Care Study Group.Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med.2000;9:160-167.
74.
McDuffie JR , Calis KA, Booth SL, Uwaifo G., Yanovski JAEffects of orlistat on fat-soluble vitamins in obese adolescents. Pharmacotherapy. 2002 ;22:814-822.
75.
Gotfredsen A., Westergren Hendel H, Andersen T.Influence of orlistat on bone turnover and body composition. Int J Obes.2001;25:1154-1160.
76.
Zhi J., Melia AT, Eggers H., Joly R., Patel IHReview of limited systemic absorption of orlistat, a lipase inhibitor, in healthy human volunteers. J Clin Pharmacol.1995;35:1103-1108.
77.
Zhi J., Mulligan TE, Hauptman JBLongterm systemic exposure of orlistat, a lipase inhibitor, and its metabolites in obese patients. J Clin Pharmacol.1999;39:41-46.
78.
Zhi J., Melia AT, Guerciolini R., Koss-Twardy S., et al. The effect of orlistat on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers. J Clin Pharmacol.1996;36:659-666.
79.
Zhi J., Moore R., Kanitra L., Mulligan TEPharmacokinetic evaluation of the possible interactions between selected concomitant medications and orlistat at steady state in healthy subjects. J Clin Pharmacol.2002;42:1011-1019.
80.
Zhi J., Moore R., Kanitra L., et al. Effects of orlistat, a lipase inhibitor, on the pharmacokinetics of three highly lipophilic drugs (amiodarone, fluoxetine, and simvastatin) in healthy volunteers. J Clin Pharmacol.2003 ;43:428-435.
81.
Krempf M., Louvet JP, Allanic H., Miloradovich T., Joubert J-M., Attali J-R.Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes.2003;27:591-597.
82.
Rissanen A. , Lean M., Rössner S., Segal KR, Sjöström L.Predictive value or early weight loss in obesity management with orlistat: an evidence-based assessment of prescribing guidelines . Int J Obes.2003;27:103-109.
83.
Heymsfield SB, Segal KR, Hauptman J., et al. Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med.2000;160:1321-1326.
84.
Lindgärde F. , on behalf of Orlistat Swedish Multimorbidity Study Group.The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish multimorbidity study. J Int Med.2000;248:245-254.
85.
Broom I., Wilding J., Stott P., Myers N.Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK multimorbidity study. Int J Clin Pract. 2002;56:494-499.
86.
Guy-Grand B. , Droulin P., Eschwège E., Gin H., Joubert J-M., Valensi P.Effects of orlistat on obesity-related diseases: a six month randomized trial. Diabetes Obes Metab. 2004;6:375-383.
87.
Swinburn BA , Carey D., Hills AP, et al. Effects of orlistat on cardiovascular disease risk in obese adults. Diabetes Obes Metab. 2005;7:254-262.
88.
Bakris G., Calhoun D., Egan B., Hellmann C., Dolker M., Kingma I.Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens.2002;20:2257-2267.
89.
Bloch KV, Salles GF, Muxfeldt ES, NogueiraAdR. Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial. J Hypertens.2003;21:2159-2165.
90.
Muls E., Kolanowski J., Scheen A, VanGaal L, for the ObelHyx Study Group. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes.2001;25:1713-1721.
91.
Lucas CP, Boldrin MN, Reaven GMEffect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol.2003;91:961-964.
92.
Erdmann J., Lippl F., Klose G., Schusdziarra V.Cholesterol lowering effect of dietary loss and orlistat treatment: efficacy and limitations. Aliment Pharmacol Ther.2004 ;19:1173-1179.
93.
Wirth A.Reduction of body weight and co-morbidities by orlistat: the XXL-primary health care trial. Diabetes Obes Metab. 2005;7:21-27.
94.
Hollander PA , Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care. 1998;8:1288-1294.
95.
Kelley DE, Bray G., Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patients with insulintreated type 2 diabetes. Diabetes Care . 2002;25:1033-1041.
96.
Miles JM, Leiter L., Hollander P., et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care. 2002;7:1123-1128.
97.
Hanefeld M. , Sachse G.The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized placebo-controlled trial. Diabetes Obes Metab. 2002;4:415-423.
98.
Berne C., on behalf of the Orlistat Swedish Type 2 diabetes Study Group.A randomized study of orlistat in combination with a weight management programme in obese patients with type 2 diabetes treated with metformin. Diabet Med.2005;22:612-618.
99.
Derosa G., Mugellini A., Ciccarelli L., Rinaldi A., Fogari R.Effects of orlistat, simvastatin, and orlistat + simvastatin in obese patients with hypercholesterolemia: a randomized, open label trial. Clin Ther Res Clin Exp. 2002;63:621-633.
100.
Derosa G., Mugellini A., Ciccarelli L., Fogari R.Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both on anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther Res Clin Exp.2003;25:1107-1122.
101.
McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res.2002;10:642-650.
102.
Ozkan B., Bereket A., Turan S., Keskin S.Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr.2004;163:738-741.
103.
Norgren S., Danielsson P., Jurold R, Lötborn, Marcus C. Orlistat treatment in obese pre-pubertal children: a pilot study. Acta Paediatr.2003 ;92:666-670.
104.
Chanoine JP, Hampl S., Jensen C., Boldrin M., Hauptmann J.Effect of orlistat on weight and body composition in obese adolescents. JAMA.2005;293:2873-2883.
105.
FDA CDER Division of Metabolic and Endocrine Drug Products (HFD-510).Clinical review for NDA 20-766/S018 . Available at: http://www.fda.gov/cder/foi/esum/2003/20766se5-018_Orlistat_BPCA_CLINICAL_ltr.pdf. Accessed July 26, 2006.
106.
Derosa G., Cicero Afg, Murdolo G., et al. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients. Diabetes Obes Metab . 2004;7:47-55.
107.
Gokcel A., Gumurdulu Y., Karakose H., et al. Evaluation of the safety and efficacy of sibutramine, orlistat, and metformin in the treatment of obesity. Diabetes Obes Metab.2002;4:49-55.
108.
Aydin N., Topsever P., Kaya A., Karasakal M., Duman C., Da ar.Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?Tohoku J Exp Med.2004;202:173-180.
109.
Wadden TA, Berkowitz RI, Womble LF, Sarwer DB, Arnold ME, Steinberg CMEffects of sibutramine plus orlistat in obese women following 1 year of treatment by sibutramine alone: a placebo-controlled trial. Obes Res.2000;8:431-437.
110.
Després JP , Golay A., Sjöström L., for the Rimonabant in Obesity-Lipids Study Group.Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med.2005;353:2121-2134.
111.
Scheen AJ, Finer N., Hollander P., Jensen MD, VanGaal LF, for the RIO-Diabetes Study Group. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomized controlled study. Lancet. 2006;368:1660-1672.
112.
Curioni C. , Andre C.Rimonabant for overweight or obesity. Cochrane Database Syst Rev.2006;(4):CD006162.
113.
Acomplia (rimonabant): investigational agent for the management of obesity. Available at: http://www.drugdevelopmenttechnology.com/projects/rimonabant/ . Accessed July 26, 2006.
114.
Information on clinical trials and human research studies rimonabant trial list. Available at: http://www.clinicaltrials.gov/ . Accessed November 12, 2006.
115.
Dansinger ML, Gleason JA, Griffith JL, Selker HP, Schaefer EJComparison of Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction. JAMA.2005;293:43-53.
116.
Curioni CC , Lourenco PMLongterm weight loss after diet and exercise: a systematic review. Int J Obes.2005;29:1168-1174.
